SETD2 and nonpapillary renal cell carcinoma: These include mutations in chromatin remodeling genes, e.g., polybromo 1 (PBRM1), SET domain containing 2 (SETD2) and BAP1, as well as activating mutations in mammalian target of rapamycin (mTOR) pathway, which are prevalent in ccRCC and associated with worse clinical outcome [11].